Novocure (NVCR) Reports Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC

Go back to Novocure (NVCR) Reports Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC

Novocure (NVCR) Climbs 45% Following Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC

April 13, 2021 7:59 AM EDT

Novocure (NASDAQ: NVCR) Climbs 45% Following Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC

... More